PAPER Jesse S, Brettschneider J, Süssmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC, Tumani H, Otto M

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

J Neurol. 2011 Jun;258(6):1034-41. Epub 2010 Dec 25 PubMed: 21188408

PAPER Li G, Chang M, Jiang H, Xie H, Dong Z, Hu L

Proteomics analysis of methylglyoxal-induced neurotoxic effects in SH-SY5Y cells.

Cell Biochem Funct. 2010 Dec 27; PubMed: 21188731

PAPER Kaiser G, Unger A, Marquart B, Weiss M, Freidl M, Wancata J

[The German language version of the Camberwell Assessment of Need for the Elderly (CANE) among dementia patients].

Neuropsychiatr. 2010;24(3):182-9. PubMed: 20926056

PAPER

Deep brain stimulation shows promise for Alzheimer's, depression treatment. Doctors also now have more options in how DBS is used to treat Parkinson's disease.

Nat Chem Biol. 2011 Feb;7(2):106-12. PubMed: 21186495

PAPER

Can diabetes affect brain function? Does it increase the risk of Alzheimer's disease?

J Neurol. 2011 Jun;258(6):1034-41. PubMed: 21188844

Carol Horntrop

Seton Family of Hospitals
Austin, United States

PAPER Steiner H, Romig H, Pesold B, Philipp U, Baader M, Citron M, Loetscher H, Jacobsen H, Haass C

Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis.

Biochemistry. 1999 Nov 2;38(44):14600-5. PubMed: 10545183

Gal Bitan on Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

COMMENT This paper addresses the question of how inhibitors of Aβ-induced toxicity work, and how they affect Aβ self-assembly. This is an important and timely question. In the past, when Aβ fibrils were thought to be the cause of Alzheimer’s disease (AD), inhibit

Aida Attar

University of California, Los Angeles
Los Angeles, United States

Huiyuan Li

University of California, Los Angeles
Los Angeles, United States

Gal Bitan

University of California, Los Angeles
Los Angeles, United States

Paul Coleman on The pathological process underlying Alzheimer's disease in individuals under thirty.

COMMENT This is a vitally important paper that provides further evidence for a "silent period" lasting many decades before AD is clinically diagnosed. The authors found abnormally hyperphosphorylated tau in subcortical regions in people between ages fou

SIRT1/Sir2

ANTIBODY polyclonal manufacturer Cat# 07-131 Immunogen = His-tagged fusion protein corresponding to amino acids 1-131 of mouse Sir2α liquid, purified, Tris-Glycine, saline, azide, glycerol recognizes SIRT1, ~110 kDa IgG Sirtuins Chemicon and Upstate are Millipore

acetylated Tau /ac-tau

ANTIBODY polyclonal laboratory 9AB<br /><a href="http://www.gladstone.ucsf.edu/gladstone/site/gan/" target="_new">Li Gan</a>, Gladstone Institute of Neurological Disease Assistant Professor of Neurology University of Californi

acetylated Tau /ac-tau

ANTIBODY polyclonal laboratory Ab708<br /><a href="http://www.gladstone.ucsf.edu/gladstone/site/gan/" target="_new">Li Gan</a>, Gladstone Institute of Neurological Disease Assistant Professor of Neurology University of Califor